Target Name: MUSK
NCBI ID: G4593
Review Report on MUSK Target / Biomarker Content of Review Report on MUSK Target / Biomarker
MUSK
Other Name(s): Muscle-specific kinase receptor | Muscle associated receptor tyrosine kinase, transcript variant 1 | FADS1 | MGC126323 | Muscle, skeletal receptor tyrosine-protein kinase | muscle-specific tyrosine-protein kinase receptor | muscle, skeletal, receptor tyrosine kinase | OTTHUMP00000021899 | Muscle, skeletal receptor tyrosine-protein kinase (isoform 1) | MGC126324 | MUSK variant 1 | FADS | muscle-specific kinase receptor | MuSK | MUSK_HUMAN | muscle associated receptor tyrosine kinase | OTTHUMP00000021900 | CMS9 | Muscle-specific tyrosine-protein kinase receptor

Targeting MSK Receptors: A Promising Approach To Therapeutic Intervention

Muscle-specific kinase (MSK) receptors are a family of transmembrane proteins that play a crucial role in muscle growth, maintenance, and repair. These receptors are involved in many physiological processes in the muscle, including muscle growth, muscle contraction, and muscle relaxation . Unfortunately, muscle-specific kinase receptors have also been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, targeting these receptors for therapeutic intervention has become an exciting area of 鈥嬧?媟esearch.

Targeting MSK Receptors

One potential approach to targeting MSK receptors is to develop small molecules that can inhibit their activity. One class of small molecules that have been shown to inhibit MSK receptor activity is the benzimidazole compounds. These molecules work by binding irreversibly to the active site of the MSK receptor, thereby preventing it from activating and leading to muscle growth.

Another approach to targeting MSK receptors is to use monoclonal antibodies (MCAs), which are laboratory-produced molecules that recognize and bind to specific antigens. MCA can be used to target MSK receptors and inhibit their activity. One company, Kymos, has developed a pipeline of MCA-based drugs for the treatment of various diseases, including cancer and neurodegenerative diseases.

Another approach to targeting MSK receptors is to use gene editing techniques to modify the genes responsible for producing MSK receptors. This approach has been used to create modified stem cells that have been shown to be resistant to radiation therapy. By using CRISPR-Cas9 to edit the genes of stem cells, researchers have been able to modify them to produce proteins that are less susceptible to radiation therapy.

Clinical Applications

Targeting MSK receptors has the potential to treat a wide range of diseases. For example, one potential approach to treating cancer is to use MSK inhibitors to inhibit the activity of MSK receptors, leading to muscle growth inhibition and potentially slowing down the growth of cancer cells . This approach could be used to treat various types of cancer, including breast, ovarian, and prostate cancer.

Another potential approach to treating MSK receptor-related diseases is to use MCAs to target and inhibit the activity of MSK receptors. This approach has the potential to treat a wide range of diseases, including neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases, as well as autoimmune disorders.

Conclusion

In conclusion, muscle-specific kinase (MSK) receptors are a promising drug target for therapeutic intervention. By developing small molecules and antibodies that can inhibit MSK receptor activity, researchers are working to treat a wide range of diseases. As research continues to advance, it is likely that new approaches to targeting MSK receptors will be discovered, leading to even more effective treatments for a variety of diseases.

Protein Name: Muscle Associated Receptor Tyrosine Kinase

Functions: Receptor tyrosine kinase which plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between the motor neuron and the skeletal muscle (PubMed:25537362). Recruitment of AGRIN by LRP4 to the MUSK signaling complex induces phosphorylation and activation of MUSK, the kinase of the complex. The activation of MUSK in myotubes regulates the formation of NMJs through the regulation of different processes including the specific expression of genes in subsynaptic nuclei, the reorganization of the actin cytoskeleton and the clustering of the acetylcholine receptors (AChR) in the postsynaptic membrane. May regulate AChR phosphorylation and clustering through activation of ABL1 and Src family kinases which in turn regulate MUSK. DVL1 and PAK1 that form a ternary complex with MUSK are also important for MUSK-dependent regulation of AChR clustering. May positively regulate Rho family GTPases through FNTA. Mediates the phosphorylation of FNTA which promotes prenylation, recruitment to membranes and activation of RAC1 a regulator of the actin cytoskeleton and of gene expression. Other effectors of the MUSK signaling include DNAJA3 which functions downstream of MUSK. May also play a role within the central nervous system by mediating cholinergic responses, synaptic plasticity and memory formation (By similarity)

The "MUSK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MUSK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MUSTN1 | MUTYH | MVB12A | MVB12B | MVD | MVK | MVP | MX1 | MX2 | MXD1 | MXD3 | MXD4 | MXI1 | MXRA5 | MXRA5Y | MXRA7 | MXRA8 | MYADM | MYADML | MYADML2 | MYB | MYBBP1A | MYBL1 | MYBL2 | MYBPC1 | MYBPC2 | MYBPC3 | MYBPH | MYBPHL | MYC | MYCBP | MYCBP2 | MYCBP2-AS1 | MYCBPAP | MYCL | MYCL-AS1 | MYCLP1 | MYCN | MYCNOS | MYCNUT | MYCT1 | MYD88 | MYDGF | MYEF2 | Myelin Protein | MYEOV | MYF5 | MYF6 | MYG1 | MYH1 | MYH10 | MYH11 | MYH13 | MYH14 | MYH15 | MYH16 | MYH2 | MYH3 | MYH4 | MYH6 | MYH7 | MYH7B | MYH8 | MYH9 | MYHAS | MYL1 | MYL10 | MYL11 | MYL12A | MYL12B | MYL12BP3 | MYL2 | MYL3 | MYL4 | MYL5 | MYL6 | MYL6B | MYL7 | MYL9 | MYLIP | MYLK | MYLK-AS1 | MYLK-AS2 | MYLK2 | MYLK3 | MYLK4 | MYLKP1 | MYMK | MYMX | MYNN | MYO10 | MYO15A | MYO15B | MYO16 | MYO16-AS1 | MYO16-AS2 | MYO18A | MYO18B | MYO19 | MYO1A